#United States #Boston #Nabsys #Genome Mapping #OhmX

Nabsys Showcases the Advantages of the OhmX™ Platform at ASHG 2025

Nabsys 2.0, LLC, a trailblazer in the realm of electronic genome mapping technology, made significant waves at the American Society of Human Genetics (ASHG) Annual Meeting, held in Boston from October 14 to 18, 2025. During the event, the company presented groundbreaking data elucidating the unique capabilities of its OhmX™ Platform for genome mapping, particularly in the field of cancer research.

In a poster presentation titled "Electronic Genome Mapping of Somatic Structural Variants" (Poster # 9031F), Nabsys showcased its advanced methodology's ability to accurately identify and validate complex structural variants (SVs) within cancer genomes. This is a notable feat, considering the limitations of current research techniques. The OhmX Platform successfully verified 420 out of 592 insertions and deletions that were larger than 300 base pairs (bp). Additionally, it demonstrated proficiency in validating somatic SVs from tumor cell lines, capable of addressing SVs ranging from 300 bp to several megabases.

Dr. John Thompson, who serves as the Principal Application Scientist at Nabsys, commented on the revolutionary aspect of this technology: "Cancer is a complex disease characterized by innumerable permutations of structural variations in the human genome. The capacity to swiftly and accurately detect these variations through electronic genome mapping signifies a substantial leap forward in personalized medicine and cancer pathology." He further explained that this approach offers a superior alternative to optical imaging methods, which are hampered by the diffraction limits of light waves, showcasing the efficiency and cost-effectiveness of electronic detection.

The OhmX Platform's contributions were met with approval from Dr. Barrett Bready, the founder and CEO of Nabsys, who expressed enthusiasm regarding the presentations made at ASHG. He acknowledged that they serve to reinforce the platform as an optimal solution for detailed SV analysis. He noted, "By bridging critical research gaps, we are committed to leveraging genome mapping technology as a powerful, scalable, and economical tool for researchers across the globe."

The implications of Nabsys's findings at the ASHG meeting extend beyond mere academic interest; they promise to enhance our understanding of genomic variations substantially, which can, in turn, improve diagnostic capabilities and patient outcomes. This move is pivotal for a future where accurate genomic analysis is routine in cancer research and treatment planning.

For those interested in accessing all presentations from the ASHG Meeting, Nabsys has made them available in the "Resources" section on their official website at www.nabsys.com/resources?category=Posters.

About Nabsys 2.0, LLC

Based in Providence, Rhode Island, Nabsys 2.0, LLC is dedicated to enhancing the understanding of diseases through reliable genomic analysis. Their mission focuses on increasing diagnostic yield and improving patient outcomes by making the analysis of genomic structural variations both routine and cost-effective. The company's growing team comprises dedicated scientists, engineers, and various professionals passionate about advancing genomic research.

To learn more about Nabsys and their innovative solutions, visit Nabsys Official Website.